Asia Pacific Allergy最新文献

{"title":"Real-world patient's practices in the management of allergic rhinitis in the Philippine setting.","authors":"Ma Lourdes B Enecilla, Marysia Stella T Recto, Cecilia Gretchen Navarro-Locsin, Joel A Romualdez, Mary Anne R Castor, Victoria Chato-Andeza, Antonio Hao Chua, Eloisa S De Guia, Charito C de Los Santos, Heidilita M Espinoza, Jenifer R Otadoy-Agustin, Josephine B Ramos, Ma Fredelita G Carreon-Asuncion, Jean Bousquet","doi":"10.5415/apallergy.0000000000000214","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000214","url":null,"abstract":"<p><strong>Background: </strong>Allergic rhinitis is a prevalent disease and there is a need for local real-world data to create relevant guidelines and care pathways in its management.</p><p><strong>Objective: </strong>The aim was to investigate the health-seeking behavior and practices of Filipinos in managing allergic rhinitis symptoms.</p><p><strong>Methods: </strong>A cross-sectional stratified online survey was conducted among Filipinos with allergic rhinitis symptoms. Stratified sampling, based on age group and region of residence in the Philippines, with proportional allocation, was used to select the respondents of this study.</p><p><strong>Results: </strong>A total of 317 respondents (213 adults and 104 pediatric) were included in the analysis. The majority (61.83%) had moderate-severe intermittent allergic rhinitis. Eighteen percent (18%) had no prior consult with a physician, while 37% had self-medicated. Sixty-three percent of participants preferred taking prescribed oral medications and 48.6% preferred a prescribed nasal spray. The most common drug classes used for allergic rhinitis were oral antihistamines (68.14%) and steroid nasal spray (34.07%). Only 45.42% admitted to being fully adherent with their prescribed medications. The most frequently cited factors that would improve compliance were cost (47.32%), few side effects (47.32%), and rapid onset of effect (40.38%). Only 21.14% of respondents had undergone allergen skin testing and 6.62% had undergone immunotherapy.</p><p><strong>Conclusions: </strong>Many Filipinos who suffer from allergic rhinitis symptoms have not been seen by a physician or, even after consultation, are not adherent to prescribed medications. There is a need for increased public awareness regarding allergic rhinitis and more effective communication between patients and the healthcare provider to improve outcomes.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"16 1","pages":"20-29"},"PeriodicalIF":2.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13060951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147643708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of xyloglucan nasal spray in children with allergic rhinitis: A randomized, double-blind, placebo-controlled, crossover study.","authors":"Piyapong Laopakorn, Potjanee Kiewngam, Wanlapa Jotikasthira, Adithep Sawatchai, Wacharoot Kanchongkittiphon, Wiparat Manuyakorn","doi":"10.5415/apallergy.0000000000000221","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000221","url":null,"abstract":"<p><strong>Background: </strong>A tamarind seed extract-based solution containing xyloglucan forms a protective layer over the nasal epithelium. However, there is no previous study evaluating xyloglucan efficacy in children with allergic rhinitis (AR).</p><p><strong>Objective: </strong>To evaluate the safety and efficacy of xyloglucan as an adjunctive treatment for AR in children.</p><p><strong>Methods: </strong>This randomized, double-blind, placebo-controlled crossover study assessed the efficacy of xyloglucan nasal spray in managing AR symptoms in children. Participants 6-18 years with AR were randomized to receive either xyloglucan or placebo in addition to their current AR therapy for 2 weeks, followed by a 2-week washout and crossover to the alternate treatment for 2 weeks. Primary outcomes were changes in visual analog scale scores analyzed using linear mixed models, adjusting for treatment, period, sequence, and compliance. Subgroup analyses included children with moderate symptoms and good compliance.</p><p><strong>Results: </strong>Seventy-nine children with AR were enrolled, median age 10 years (IQR: 8-12). Treatment with xyloglucan was associated with a significantly greater reduction in nasal congestion compared to placebo (β = -1.013, 95% confidence interval [CI], -1.729 to -0.298, <i>P</i> = 0.006). In children with moderate symptoms and good compliance, the effect on nasal congestion was more pronounced (β = -1.588, <i>P</i> = 0.046). Improvements in rhinorrhea, sneezing, and itching were observed but did not reach statistical significance. Both treatments were well tolerated, with only mild adverse events in both groups.</p><p><strong>Conclusion: </strong>Xyloglucan nasal spray, as an adjunct to standard AR treatment, demonstrated potential benefits in alleviating rhinitis symptoms, particularly nasal congestion, in children with AR. This clinical trial was registered with the Thai Clinical Trials Registry (No. TCTR20240318004).</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"16 1","pages":"14-19"},"PeriodicalIF":2.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13060874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147643728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IL-7 in colostrum is associated with atopic dermatitis at 9 months of age: A birth cohort in Japan.","authors":"Saori Abe, Daisuke Furushima, Kazutoshi Sayama, Naoki Shimojo","doi":"10.5415/apallergy.0000000000000219","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000219","url":null,"abstract":"<p><strong>Background: </strong>CCL25, CCL28, and IL-7 are present in breast milk and are known to contribute to the infant's thymus function and mucosal immune system. However, little is known about the relationship between the concentration of these cytokines/chemokines in breast milk and the development of atopic dermatitis (AD) in infancy.</p><p><strong>Objective: </strong>The purpose of this study was to investigate whether the concentration of these cytokines/chemokines in breast milk is related to the development of AD in infants.</p><p><strong>Methods: </strong>In this study, we measured the concentrations of cytokines/chemokines in colostrum collected within 5 days of birth and in breast milk collected at 1-month of birth in 281 infants belonging to a birth cohort using sandwich ELISA, and analyzed the relationship with the development of AD in infants at 9 months of age.</p><p><strong>Results: </strong>There was no association between CCL25 and CCL28 levels in breast milk and 9-month AD. On the other hand, IL-7 levels in colostrum ingested by AD infants were significantly higher than those ingested by non-AD infants (median, ng/mL: 0.186 vs 0.119, Mann-Whitney <i>U</i> test, <i>P</i> < 0.01). In addition, IL-7 showed a significant dose-dependent relationship with AD. This relationship was only observed in mothers with allergies.</p><p><strong>Conclusion: </strong>The results of this study show that IL-7 levels in breast milk may offer insights into the pathophysiological mechanisms of infantile AD.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"16 1","pages":"30-35"},"PeriodicalIF":2.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13061012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147643726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review of the outcomes of desensitization for delayed-type cutaneous adverse reactions induced by antituberculosis drugs.","authors":"Kanokkarn Pinyopornpanish, Kanokporn Pinyopornpanish, Suphawita Pliannuom, Chaisiri Angkurawaranon, Wannada Laisuan","doi":"10.5415/apallergy.0000000000000242","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000242","url":null,"abstract":"<p><strong>Background: </strong>Tuberculosis remains a significant global health concern, affecting millions of people worldwide. Treatment usually involves a combination of drugs; however, drug hypersensitivity reactions pose challenges, particularly due to the diversity of side effects. Cutaneous reactions are common, ranging from maculopapular rash to severe conditions such as drug reaction with eosinophilia and systemic syndrome and Stevens-Johnson syndrome/toxic epidermal necrolysis syndrome. Rechallenge with the same drugs is often practiced, but desensitization has emerged as an alternative in the mitigation of reactions, especially in an outpatient setting.</p><p><strong>Methods: </strong>We conducted a systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and searched PubMed, EMBASE, Cochrane Library, and CINAHL databases. Studies were included if they involved patients with tuberculosis receiving rechallenge or desensitization, reported postdesensitization outcomes, and were published in English. Data extraction and analysis were independently performed by 2 reviewers.</p><p><strong>Results: </strong>The literature search identified 4,560 potentially eligible articles, of which 7 studies comprising 102 patients met the inclusion criteria. Desensitization success rates ranged from 78.9% to 100% with a range of protocols employed across studies. Investigations such as patch tests and lymphocyte transformation tests have helped in ensuring accurate diagnosis and guided desensitization strategies.</p><p><strong>Conclusion: </strong>Desensitization is an effective strategy for the management of adverse reactions to antituberculosis drugs, particularly in cases of delayed cutaneous adverse reactions.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"16 1","pages":"65-73"},"PeriodicalIF":2.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13061011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147643752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blended reactions and angioedema are common in patients with cross-reactive nonsteroidal anti-inflammatory drug hypersensitivity.","authors":"Duy Le Pham, Huy Duc Le, Diep Khang Nguyen, Viet Hoang Nguyen, Nghi Man Ly, Huong Thi Bich Le, Son Xuan Huu Nguyen, Loc Duc Nguyen, Thu Trang Nguyen Mai, Khoa Anh Nguyen, Quoc Quang Luu, Hoang Kim Tu Trinh","doi":"10.5415/apallergy.0000000000000211","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000211","url":null,"abstract":"<p><strong>Background: </strong>The European Academy of Allergology and Clinical Immunology (EAACI)/The Global Allergy and Asthma European Network (GA²LEN) guidelines recognize 3 phenotypes of cross-reactive nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity (NHS): NSAID-induced urticaria/angioedema (NIUA), NSAID-exacerbated cutaneous disease (NECD), and NSAID-exacerbated respiratory disease (NERD). However, numerous cases cannot be neatly classified into any of these groups.</p><p><strong>Objective: </strong>This study investigated the phenotypes of cross-reactive NHS in Vietnamese patients.</p><p><strong>Methods: </strong>Our retrospective study of 141 patients with cross-reactive NHS was conducted at the Allergy and Clinical Immunology Unit, University Medical Center Ho Chi Minh City, Vietnam. Patients were diagnosed with cross-reactive NHS if they had 3 or more reactions involving 3 or more different NSAIDs. Patients with an unclear history underwent single-blind oral challenge tests with aspirin to diagnose cross-reactive NHS. Reactions that did not align with any of the 3 standard phenotypes were defined as blended reactions (BRs).</p><p><strong>Results: </strong>Among the 125 patients with cross-reactive NHS who exhibited cutaneous symptoms, 113 (90.4%) had angioedema with or without wheals and 12 (9.6%) had isolated wheals. However, the most common phenotype according to the EAACI classification was NIUA (66/141, 46.8%), followed by NECD (8/141, 5.7%) and NERD (4/141, 2.8%). BRs were determined in 63 patients (44.7%). The most common causative drug was paracetamol (63.8%). The alternative NSAIDs tolerated by most of the patients were etoricoxib (97.2%), celecoxib (95.9%), and meloxicam (94.3%).</p><p><strong>Conclusions: </strong>BRs are a common phenotype in patients with cross-reactive NHS. Angioedema, with or without wheals, is an important clinical manifestation suggesting a cross-reactive NHS response. Highly selective COX-2 inhibitors are likely to be tolerated by most patients with cross-reactive NHS.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"16 1","pages":"8-13"},"PeriodicalIF":2.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13060876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147643755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The interconnection between environment, immune-nutrition and allergic disease.","authors":"Ruby Pawankar, Luo Zhang","doi":"10.5415/apallergy.0000000000000263","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000263","url":null,"abstract":"","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"16 1","pages":"1-2"},"PeriodicalIF":2.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13060950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147643763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intradermal injection of human sweat enhances production of specific IgG against antigens solved in the sweat.","authors":"Kaori Ishii, Yuhki Yanase, Kazue Uchida, Michihiro Hide, Akio Tanaka","doi":"10.5415/apallergy.0000000000000200","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000200","url":null,"abstract":"","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"16 1","pages":"74-76"},"PeriodicalIF":2.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13061056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147643750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunonutrition: Feeding the gut, skin, and immune system.","authors":"Klaudia Ryczaj, Ruby Pawankar, Carina Venter","doi":"10.5415/apallergy.0000000000000262","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000262","url":null,"abstract":"<p><strong>Background: </strong>Early life is a critical period for the maturation of the gut microbiota, epithelial barriers, and immune system. Disruption of gut and skin barrier integrity during this window is increasingly recognized as a key mechanism contributing to the development of allergic diseases.</p><p><strong>Objective: </strong>This review summarizes evidence on how infant dietary patterns and macronutrients influence epithelial barriers, microbiota development, and immune programming for allergy prevention.</p><p><strong>Methods: </strong>A comprehensive search and analysis of current literature regarding macronutrients, including carbohydrates and fiber, proteins, and fats, dietary diversity, and Western-type dietary patterns, was conducted to explore their collective effects on epithelial barrier function, microbiota, and immune outcomes during pregnancy and early life. Particular attention was given to complementary feeding.</p><p><strong>Results: </strong>Dietary composition significantly influences epithelial barrier integrity and immune development through direct nutritional effects and microbiota-mediated pathways. Dietary fibers and human milk oligosaccharides promote short-chain fatty acid production and microbial diversity, strengthening epithelial junctions, mucus secretion, and regulatory immune responses. Adequate protein intake supports epithelial renewal, while microbial metabolism of amino acids such as tryptophan and branched-chain fatty acids enhances barrier integrity and immune homeostasis. Dietary fats critically shape epithelial lipid composition, with balanced omega-3 and omega-6 fatty acids supporting barrier resilience, whereas excess saturated and trans fats promote dysbiosis and inflammation. Furthermore, greater dietary diversity during pregnancy and infancy correlates with enhanced microbial maturation and reduced atopic risk. Conversely, Western-type diets rich in ultra-processed foods and additives disrupt epithelial barriers and promote pro-inflammatory immune programming with long-lasting consequences beyond infancy.</p><p><strong>Conclusions: </strong>Optimizing maternal and early life nutrition through breastfeeding support, timely and diverse complementary feeding, adequate intake of fiber, high-quality proteins and fats, and avoidance of Western-type dietary patterns represents a promising strategy to support gut and skin barrier and to reduce the risk of allergic diseases across the lifespan.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"16 1","pages":"45-55"},"PeriodicalIF":2.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13060806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147643743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of public health emergencies on allergen immunotherapy practices: A cross-sectional study on COVID-19 and physicians' perspectives in China.","authors":"Xiao Liu, Jinling Liu, Rong Jin, Lixia Li, Ruijia Bai, Zhuanggui Chen, Pingping Zhang","doi":"10.5415/apallergy.0000000000000235","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000235","url":null,"abstract":"<p><strong>Objective: </strong>To systematically evaluate how the COVID-19 pandemic transformed the clinical management of allergen-specific immunotherapy (AIT) in China and to establish an evidence-based AIT management strategy during future infectious disease outbreaks.</p><p><strong>Methods: </strong>This multicenter, cross-sectional survey was conducted in January 2025, involving 224 physicians with practical experience in AIT across 3 regions in China. Using a structured electronic questionnaire distributed via the Wenjuanxing platform, we systematically evaluated: physicians' basic information, the impact of the pandemic on AIT-related clinical decision-making, and the influence of COVID-19 vaccination on AIT. Data were analyzed using descriptive statistics, Pearson chi-square/Fisher exact tests, and multinomial logistic regression.</p><p><strong>Results: </strong>Among surveyed physicians, 70.5% maintained standard AIT initiation during the pandemic. Most physicians (64.9% for subcutaneous injections, 57% for sublingual administration) implemented a conservative 8- to 14-day interval between AIT and COVID-19 vaccination, exceeding the 7-day EAACI recommendation, with variations based on physician AIT experience (<i>P</i> = 0.048) and patient volume (<i>P</i> = 0.034). And most physicians recommended for no AIT dose adjustments after vaccination.</p><p><strong>Conclusion: </strong>This study documents how Chinese physicians adapted AIT practices during COVID-19. These clinician-developed strategies provide an applicable framework for maintaining AIT safety and efficacy during future public health crises while informing evidence-based guideline development.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"16 1","pages":"36-44"},"PeriodicalIF":2.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13061010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147643695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regular antigen ingestion in repeat oral food challenges: Implications for egg allergy management.","authors":"Suguru Watanabe, Takanori Imai, Kosei Yamashita, Megumi Okawa, Toshiyuki Takagi, Aiko Honda, Chihiro Kunigami, Yuki Okada, Mayu Maeda, Taro Kamiya","doi":"10.5415/apallergy.0000000000000232","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000232","url":null,"abstract":"<p><strong>Background: </strong>Oral food challenge is the most reliable test for diagnosing food allergies. Patients with food allergies who test positive in an oral food challenge should repeat the test after a certain period. Numerous studies have investigated the risk factors associated with positive outcomes; however, no studies have examined the effect of regular antigen ingestion on repeat oral food challenge results.</p><p><strong>Objective: </strong>This study retrospectively investigated the impact of regular antigen ingestion in available intake quantities on repeat oral food challenge results in patients with egg allergies.</p><p><strong>Methods: </strong>Patients who had positive initial oral food challenges with one-eighth of a heated whole hen egg and who underwent the same food challenge after a certain period were included in the study. The predictors of positive repeat oral food challenge outcomes were examined. The analysis considered age, sex, symptom grade at the initial oral food challenge, number of days between challenges, hen egg consumption status, comorbid allergic diseases, immunoglobulin E levels, and food challenge results from medical records.</p><p><strong>Results: </strong>This study included 109 patients, of whom 45 (41%) had a positive repeat oral food challenge. A significantly greater proportion of patients in the positive group in repeat oral food challenge completely avoided eggs between challenges than in the negative group (69% vs 42%, respectively, <i>P</i> = 0.006). Furthermore, the positive group had significantly greater levels of ovomucoid-specific immunoglobulin E than the negative group (<i>P</i> = 0.003). Multivariate regression analysis revealed that the \"complete elimination of hen eggs from the initial to repeat oral food challenge\" was the most pivotal factor associated with positive repeat outcomes, with an odds ratio of 3.479 (95% confidence interval, 1.327-9.125).</p><p><strong>Conclusion: </strong>In the management of submoderate hen egg allergy, avoiding complete elimination and regularly ingesting the available quantity can be a useful alternative to conventional management methods.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"16 1","pages":"3-7"},"PeriodicalIF":2.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13060777/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147643758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}